For two years, Pfizer was the big drugmaker conspicuously missing from the obesity boom. Its first marketed answer is not a homegrown pill or a U.S. launch. It is ecnoglutide, a once-weekly GLP-1 injection developed by Hangzhou-based Sciwind Biosciences, licensed to Pfizer for mainland China and launched there in April 2026.
On November 3, Pfizer executives used their third-quarter earnings call to explain how they intend to compete: by drawing on lessons from Viagra, the company’s famous erectile dysfunction medicine, and the experience of selling products to consumers willing to pay out of pocket.
The comparison is revealing. Pfizer is entering a crowded Chinese obesity market with a product it did not develop, a commercial strategy that emphasizes self-pay demand, and a reimbursement decision that remains unresolved.
The critical question is whether patients will continue paying for a chronic medicine while Pfizer works to secure the kind of diabetes reimbursement access already available to several competitors.
How Pfizer Got Its First Marketed Obesity Drug in China
Pfizer acquired exclusive mainland China commercialization rights to ecnoglutide in February 2026 through a deal with Sciwind Biosciences valued at up to $495 million. That total includes an undisclosed upfront payment and potential regulatory and sales milestones. It is not an amount Pfizer necessarily paid at signing.
Under the agreement, Sciwind remains the marketing authorization holder and retains responsibility for research, development, regulatory registration, manufacturing and supply. Pfizer’s role is to commercialize the medicine in mainland China, using its established operations and distribution relationships.
The regulatory groundwork had already begun before Pfizer entered the arrangement. China’s National Medical Products Administration approved ecnoglutide for adults with type 2 diabetes in January 2026. On March 6, regulators authorized the injection for chronic weight management in adults with overweight or obesity, alongside dietary changes and physical activity.
Pfizer subsequently launched ecnoglutide in China on April 27. It was an unusually direct route into the obesity market for a company whose internal GLP-1 development efforts had encountered setbacks.
The drug itself is a cAMP-biased GLP-1 receptor agonist. That designation describes the way the molecule preferentially activates particular intracellular signaling pathways after binding to the GLP-1 receptor. Sciwind has described it as the first approved medicine of its kind for weight management.
The distinction may be scientifically interesting, but it should not be mistaken for proof that ecnoglutide is clinically superior to semaglutide, tirzepatide or other marketed obesity treatments. That question requires appropriately designed comparative evidence.
What the Ecnoglutide Clinical Data Actually Show
The efficacy numbers behind the launch are more detailed than the promotional summaries suggest.
In the SLIMMER Phase 3 trial, published in The Lancet Diabetes & Endocrinology in 2025, researchers randomized 664 Chinese adults with overweight or obesity, without diabetes, at 36 research centers. Participants received once-weekly ecnoglutide at one of three doses or placebo, alongside lifestyle intervention.
The study’s coprimary outcomes were assessed at week 40, when the 2.4 mg group had an estimated mean body-weight reduction of 13.2%, compared with a 0.1% increase in the placebo group. The estimated treatment difference was approximately 13.3 percentage points.
The widely cited 15.1% placebo-adjusted weight-loss figure comes from the trial’s later, 48-week findings. At that point, the highest-dose group had lost approximately 15.4% of baseline body weight, compared with approximately 0.3% in the placebo group. About 92.8% of participants receiving the 2.4 mg dose achieved at least 5% weight loss.
Those figures are meaningful, but they describe a specific study population, treatment duration and dose. They are not guaranteed outcomes for every Chinese patient receiving the marketed medicine. Nor can they establish superiority over rival GLP-1 products tested in separate trials.
Gastrointestinal adverse events were common. In the published trial, nausea, vomiting, diarrhea and reduced appetite were among the reported effects, while ten participants receiving ecnoglutide discontinued treatment because of adverse events.
The commercial question, then, is not simply whether ecnoglutide can reduce weight. Randomized evidence indicates that it can. The harder question is how efficacy, tolerability, affordability and treatment persistence will influence demand in a Chinese market with multiple approved alternatives.
Pfizer has an approved obesity medicine in China. What it does not yet have is clear evidence that its self-pay launch can become a large, durable business.
The Viagra Playbook: People Pay for Products They Value
On Pfizer’s November 3 earnings call, chief executive Albert Bourla compared the commercial opportunity in obesity treatment with the company’s experience launching Viagra.
His argument was that some consumers will pay out of pocket for medicines they value, whether or not those medicines are reimbursed. Bourla also emphasized the role of e-commerce, the internet and consumer-directed communication in expanding access to pharmaceutical products.
BioSpace reported the remarks as Pfizer looks to apply lessons from Viagra to its new obesity business. The analogy is about consumer behavior and distribution strategy, rather than an identical sales model.
Pfizer has already built experience with consumer-facing medicine distribution through initiatives such as PfizerForAll. Bourla pointed to the broader company’s digital commercial capabilities, including products such as Nurtec and Paxlovid, as examples of how Pfizer is learning to engage consumers outside traditional pharmaceutical sales channels.
Alexandre de Germay, Pfizer’s chief international commercial officer, described the Chinese weight-management market as containing different patient segments. Some patients place greater emphasis on appearance-related weight loss, while others seek substantial weight reduction and may evaluate the balance between efficacy and tolerability differently.
That segmentation helps explain Pfizer’s preference for building a portfolio rather than relying on a single medicine. Different products can serve different patient needs, while the commercial infrastructure required to reach those patients can potentially support several treatments.
But the Viagra comparison has a limit. Viagra is generally used as needed. Ecnoglutide is a once-weekly treatment intended for ongoing management of a chronic condition. For patients who must continue paying, affordability can become more consequential over time.
There is a difference between persuading someone to make an initial purchase and supporting treatment over many months. A strong launch does not establish strong long-term persistence.
The Viagra analogy may explain how Pfizer attracts a customer. It cannot, by itself, explain how that customer affords a year of treatment.
The Reimbursement Gap Is Mostly About Diabetes Coverage
The missing piece in Pfizer’s commercial strategy is reimbursement, but the distinction between diabetes and obesity coverage is essential.
China’s National Reimbursement Drug List provides public medical insurance coverage for eligible medicines under specified conditions. Established GLP-1 drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro have secured reimbursement for type 2 diabetes. That does not mean their weight-management indications automatically receive the same coverage.
Ecnoglutide passed a preliminary review for potential inclusion in China’s national reimbursement system in June 2026. At the November 3 earnings call, de Germay said the company expected a final review by the end of the month and hoped to gain access to the hospital reimbursement system.
The distinction matters because ecnoglutide has two approved uses, while public reimbursement for GLP-1 drugs in China has primarily concerned diabetes treatment. A successful reimbursement negotiation would therefore not necessarily make ecnoglutide publicly funded for weight loss.
There is an additional regulatory detail that deserves care. Sciwind announced the original NMPA approval for type 2 diabetes in January. During Pfizer’s November call, de Germay also referred to a diabetes-related approval milestone achieved at the end of October, which he said improved access to hospital and e-commerce channels. The available remarks do not clearly reconcile those two dates, so the October reference should not be represented as the medicine’s first diabetes authorization.
Reimbursement can change the commercial economics of a product. Access through the public system may expand the eligible patient base, improve hospital availability and reduce direct patient costs for covered uses. But reimbursement negotiations can also lead to lower manufacturer prices, meaning increased volume does not translate automatically into proportionate revenue growth.
This leaves Pfizer facing two overlapping markets. One includes patients receiving approved diabetes treatment through established medical channels. The other includes people seeking chronic weight management who may be paying privately.
Those markets have different reimbursement constraints, treatment objectives and purchasing decisions. Treating them as a single undifferentiated obesity market would obscure the central challenge Pfizer is trying to solve.
For Pfizer, a diabetes reimbursement decision could open important commercial doors. It would not automatically eliminate the self-pay challenge for obesity treatment.
A China-First Route Into a Crowded Obesity Market
Pfizer’s China-first launch also reflects how the industry’s obesity development map has changed.
In April 2025, Pfizer discontinued its experimental oral GLP-1 drug danuglipron after a participant in a dose-optimization study experienced possible drug-induced liver injury. The event resolved after the medicine was stopped, but Pfizer concluded that the overall development program should end.
Without an advanced in-house oral obesity product, Pfizer turned increasingly toward acquisitions and partnerships.
In November 2025, Pfizer completed its acquisition of Metsera after competing with Novo Nordisk for the biotechnology company. The completed transaction carried approximately $7 billion in upfront enterprise value, with contingent payments that could raise its total value toward $10 billion.
In December, Pfizer signed an exclusive global collaboration with China’s YaoPharma for YP05002, an experimental oral small-molecule GLP-1 receptor agonist. That agreement included $150 million upfront and up to $1.935 billion in additional milestone payments.
The following February, the Sciwind licensing agreement gave Pfizer something different: an already approved medicine that it could commercialize in mainland China while its broader obesity pipeline continued through development.
That is the commercial side of a trend Grey Pepper examined in its coverage of Novo Nordisk’s multibillion-dollar agreement for a Chinese-developed weight-loss pill. China is no longer merely a manufacturing or distribution market for Western pharmaceutical companies. It is increasingly a source of compounds, clinical programs and business development opportunities.
Pfizer’s longer-term global ambitions rest particularly on the Metsera assets. Its lead GLP-1 candidate, berobenatide, is being advanced through a program of ten pivotal studies, including work on monthly administration, switching from weekly GLP-1 injections, knee osteoarthritis and obstructive sleep apnea.
Pfizer is also investigating an amylin-related treatment candidate, PF-3945, including combination development with berobenatide. Those programs could eventually support a broader obesity franchise, but clinical development and regulatory approvals remain ahead.
Meanwhile, the established competitors continue to generate enormous revenue. As Grey Pepper reported in its analysis of Lilly’s third-quarter earnings, Mounjaro and Zepbound produced more than $16 billion in combined worldwide sales in a single quarter.
That comparison helps place Pfizer’s China launch in perspective. Ecnoglutide gives Pfizer real commercial participation in a fast-growing category. It does not yet make Pfizer a global obesity leader.
What to Watch Next
Three developments will help determine whether Pfizer’s ecnoglutide launch becomes a meaningful business rather than a regional starting point.
The first is the result of China’s reimbursement negotiations. Pfizer’s executives expect a decision to emerge after the review process described on the November call. The outcome will matter especially for eligible diabetes patients and hospital access, although any coverage must be understood according to its actual approved payment conditions.
The second is commercial disclosure. Pfizer has expressed satisfaction with the launch’s progress but has not provided separately identifiable ecnoglutide revenue in its Q3 reporting. Without sales, prescribing and patient-persistence figures, it is difficult to judge how far self-pay demand can carry the product.
The third is Pfizer’s broader obesity pipeline. Berobenatide and other candidates will determine whether the company eventually competes internationally with a differentiated portfolio, rather than relying primarily on a licensed medicine in one country.
The central experiment is already underway. Pfizer is testing whether a Chinese-developed GLP-1 drug can gain a foothold through self-pay sales while the company works toward wider reimbursed access for eligible patients.
That may be a pragmatic way to enter the market. It also illustrates the distance Pfizer still has to travel.
The company that made Viagra a global commercial phenomenon now hopes to apply some of the same lessons to obesity treatment. But the economics of a chronic, once-weekly injection are different from those of an as-needed medicine.
Pfizer may know how to persuade patients to pay. The question is whether China’s healthcare system and the realities of long-term treatment will allow enough of them to keep paying.
Sources and Further Reading
- BioSpace: Pfizer, Fresh to China’s Obesity Market, Looks to Viagra Model to Compete, November 3, 2026.
- Pfizer Q3 2026 Earnings Call Transcript, November 3, 2026.
- Sciwind Biosciences: Pfizer China Commercialization Agreement, February 24, 2026.
- Sciwind Biosciences: NMPA Approval of Ecnoglutide for Chronic Weight Management, March 6, 2026.
- Ji L, et al. Efficacy and Safety of Ecnoglutide in Adults With Overweight or Obesity: Phase 3 SLIMMER Trial. The Lancet Diabetes & Endocrinology, 2025.
- The Lancet Diabetes & Endocrinology: Full SLIMMER Study, Including 48-Week Results.
- Reuters: Pfizer and Innovent GLP-1 Drugs Pass China Insurance Preliminary Review, June 29, 2026.
- Pfizer: Completion of Metsera Acquisition, November 13, 2025.
- Pfizer: YaoPharma GLP-1 Licensing Agreement, December 9, 2025.
- Pfizer: Danuglipron Development Discontinued, April 14, 2025.
- Pfizer: Pipeline and Key Anticipated 2026 Catalysts.
